Catalent Pharma Solutions begins trading on the New York Stock Exchange Thursday under the ticker CTLT. Catalent's president and chief executive officer John Chiminski tells TheStreet's Brittany Umar why the company says it's the number one drug delivery technology company in the world and how it supports big pharmaceutical names like Johnson & Johnson and GlaxoSmithKline. In light of Federal Reserve chair Janet Yellen's recent comments that some firms in the biotech industry appear to have stretched valuations, Chiminski also offers his thoughts on whether a bubble is forming in the biotech sector.

If you liked this article you might like

With Hurricane Harvey, We Are in the Crosshairs of Volatility: Market Recon

With Hurricane Harvey, We Are in the Crosshairs of Volatility: Market Recon

Bullish and Bearish Reversals for the Week

Bullish and Bearish Reversals for the Week

2 Big Companies and 1 Small One to Target in the Pharma/Biotech Space

2 Big Companies and 1 Small One to Target in the Pharma/Biotech Space

Catalent (CTLT) Stock Slumps on Secondary Stock Offering

Catalent (CTLT) Stock Slumps on Secondary Stock Offering

No Fear of the Fed for Futures or in Asia

No Fear of the Fed for Futures or in Asia